Executive change adds experience to Viking Therapeutics' clinical ambitions

Viking Therapeutics (VKTX) recently drew fresh attention after analyst reports highlighted the potential of obesity drug candidate VK2735, and the company added further depth by appointing Hubert C. Chen, M.D., as chief medical officer.

For investors watching Viking Therapeutics stock, Dr. Chen’s background across drug discovery, clinical development, and regulatory strategy adds another layer to the story around VK2735 and the broader pipeline in metabolic and endocrine disorders.

Recent interest around VK2735 and the new chief medical officer appointment comes against a mixed trading backdrop, with Viking Therapeutics’ share price down 14.23% year to date, its 1 year total shareholder return at 16.80%, and its 5 year total shareholder return at 351.41%. This points to momentum that has eased in the short term while remaining strong over longer periods.

If this kind of clinical catalyst has caught your attention, it could be worth widening the net to other healthcare opportunities and checking out our screener of 40 healthcare AI stocks

With Viking Therapeutics stock down 14.23% year to date but still showing a 351.41% total return over five years and trading at a small discount to analyst targets, is there real upside left here, or is the market already pricing in future growth?

Most Popular Narrative: 67.2% Undervalued

Viking Therapeutics last closed at $30.38, while the most followed narrative points to a fair value of $92.72, putting a lot of weight on VK2735 and the wider obesity pipeline.

Parallel development of subcutaneous and oral formulations of the same GLP-1 and GIP co agonist, including plans to start Phase III oral trials and an oral maintenance strategy, directly responds to rising patient interest in flexible obesity treatment options and could support broader market reach and future earnings growth.

Want to see why this narrative leans so heavily on obesity treatments, flexible dosing and future margins? The core assumptions sit in revenue ramp, profit uplift and a very demanding earnings multiple. Curious which specific financial swing factors are doing the heavy lifting behind that fair value gap?

Result: Fair Value of $92.72 (UNDERVALUED)

However, this Viking Therapeutics story could change quickly if VANQUISH trial results disappoint or if heavier spending forces fresh equity raises that dilute shareholders.

Another view on Viking Therapeutics using P/B

The earlier fair value of $92.72 leans on long term earnings assumptions for Viking Therapeutics, but the current P/B ratio of 7x tells a different story. That is higher than both US Biotechs at 2.5x and peers at 4.4x, which pushes valuation risk higher if expectations are not met.

If you prefer to ground decisions in current balance sheet metrics rather than long range earnings forecasts, this gap in P/B versus peers and the wider industry is a reminder to stress test your own assumptions about trial outcomes and future capital needs before acting. See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

If the mixed signals around Viking Therapeutics have you undecided, it makes sense to check the details yourself and move quickly while sentiment is still forming. To round out your view on risks that others are watching, start with these 2 important warning signs

Looking for more investment ideas beyond Viking Therapeutics?

Do not stop with Viking Therapeutics when there are other opportunities worth a closer look. Use the Simply Wall Street Screener today to broaden your watchlist intelligently.

• Spot potential bargains early by scanning companies trading on compelling valuations through the 45 high quality undervalued stocks.
• Prioritize resilience by focusing on businesses that pair lower risk profiles with sturdier fundamentals using the 66 resilient stocks with low risk scores.
• Hunt for underfollowed opportunities with strong financial footing by checking the screener containing 19 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.